New method promises fewer side-effects from cancer drugs
A recent achievement in the field of protein research allows for better tailored pharmaceuticals with fewer side-effects. The method was developed by two University of Copenhagen researchers.
Protein research is one of the hottest areas in medical research because proteins make it possible to develop far more effective pharmaceuticals for the treatment of diabetes, cancer and other illnesses.
However, while proteins have great potential, they also present great challenges for scientists. Proteins have incredibly complex chemical structures that make them difficult to modify. As a result, researchers have been looking for a tool to modify them more precisely, without increasing a drug’s side-effects.
"We often run the risk of not being approved by health authorities because protein-based drugs lack precision and may have side-effects. Among other things, this is because of the serious limitations with the tools that have been used up until now,” according to Professor Knud J. Jensen of the University of Copenhagen’s Department of Chemistry.
Together with his research colleague, Sanne Schoffelen, he has developed a new protein-modifying method that promises fewer side-effects and could be pivotal in furthering the development of protein-based pharmaceuticals. Their work has been published in the distinguished journal, Nature Communications.
Protein structure is like an intricate ball of yarn
Researchers call the method "His-tag acylation". Among other things, it makes it possible to add a toxic molecule to proteins that can attack sick cells in a cancer-stricken body without attacking healthy ones.
"Proteins are like a ball of yarn, a long thread of amino acids, which are turned up. This method allows us to precisely target these intricate structures, as opposed to making uncertain modifications when we don’t know what is being hit within the ball of yarn. In short, it will help produce drugs where we can be far more confident about where modifications are being made, so that side effects can be minimized in the future,” says Knud J. Jensen.
Modified proteins must target precisely
The fact that His-tag acylation can accurately target these complex yarn-like protein structures also makes it possible to produce drugs with entirely new characteristics.
For example, researchers can now attach a fluorescent molecule to proteins in such a way that a microscope can be used to track a protein’s path through cells. The primary function of these proteins is to transport cancer fighting molecules around to sick cells, so it is important to carefully follow their path throughout the body in order to safely produce medications that don’t have unintended side-effects.
The method is an achievement in the field of protein research and yet another triumph that adds to Denmark’s strong reputation in the field of protein research chemistry.
"Because of the tremendous opportunities afforded by proteins, it is an area of significant competition, and an area where it is possible to make a lasting mark on research and development," concludes Knud J. Jensen.
The study is published in Nature Communications: